We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| RELX PLC | NYSE:RELX | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.42 | 1.02% | 41.63 | 42.34 | 41.965 | 42.33 | 974,422 | 22:30:00 |
From May 2019 to May 2024
By Adria Calatayud
RELX PLC said Thursday that revenue from its exhibitions business fell 70% for the first nine months of the year, but that its three largest business areas continued to gradually improve during the third quarter.
The FTSE 100 information and analytics group said it now expects exhibitions revenue for the full year to be between 330 million and 360 million pounds ($433.9 million-$473.3 million), and costs for the unit to be between GBP530 million and GBP540 million excluding one-off costs related to restructuring and cancellations.
The company behind the Lancet medical journal and the London Book Fair said the outlook for its three largest businesses--scientific, technical and medical, risk and business-analytics, and legal--remains unchanged.
For the first nine months of the year, underlying revenue rose 2% at RELX's scientific, technical and medical business, 3% at its risk and business-analytics unit and 1% at its legal division.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 22, 2020 02:35 ET (06:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year RELX Chart |
1 Month RELX Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
